OUR TEAM

We’ve brought together a team of international experts with a depth of experience in the development of novel therapeutics gained from leading pharmaceutical and biotechnology companies. They have worked across different disease areas and with a range of therapeutic modalities.

Susan Hill

Chief Executive Officer

Susan Hill
Chief Executive Officer
Susan Hill is Chief Executive Officer of Mestag Therapeutics. Susan joined Mestag from Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments. She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.

Ray Jupp

Chief Scientific Officer

Ray Jupp
Chief Scientific Officer
Ray Jupp is the CSO of Mestag Therapeutics. Prior to this Ray was CSO of Enara Bio. Prior to joining Enara Bio, Ray was the founding CSO of TRex Bio, a discovery stage company focused on the functional manipulation of T-regulatory cells in a tissue-specific and disease-specific fashion to deliver transformative therapies for multiple disease indications. Previously, Ray was head of the Immunology/Inflammation therapeutic area at UCB where he drove multiple compounds into development and through phase 1 and 2 trials. Ray has also held research and development leadership roles at Sanofi, Aventis, Rhone-Poulenc Rorer and Roche, where he developed deep expertise in the fields of inflammation, immunology, and infectious disease. Ray graduated with a PhD in Biochemistry from Cardiff University, followed by a post-doctoral fellowship at the Scripps Research Institute, San Diego.

James Legg

SVP R&ED

James Legg
SVP R&ED
Before joining Mestag James was SVP Research at Crescendo Biologics where he was responsible for managing Crescendo’s Immuno Oncology Portfolio from research through to preclinical development. James has 17 years’ experience in biologics drug discovery, mostly in the oncology area and has been responsible for the successful progression of multiple oncology biologics programmes through the research phases of drug discovery into preclinical development. Prior to joining Crescendo, James was a member of the oncology leadership team at MedImmune, the Biologics arm of AstraZeneca and held key scientific positions at Cambridge Antibody Technology. James has a BSc in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research with Fiona Watt at Imperial Cancer Research Fund (now CRUK) in London.

Robert de Jonge

Head of Corporate Development

Robert de Jonge
Head of Corporate Development
Robert de Jonge is the Head of Corporate Development of Mestag Therapeutics. Robert has broad background in business and corporate development in biotech. He joined Mestag from Cellinta, where he was the Head of Corporate Development. Previously, he was the Head of Business Development at Tusk Therapeutics, an immuno oncology company developing antibody therapeutics for the treatment of cancer. At Tusk, he was responsible for the company’s business development activities. He was closely involved in the sale of Tusk to Roche (€655m, €70m upfront). Robert also served as the Chief Executive Officer of Black Belt Therapeutics; an oncology company focused on targeting the stress response pathways in cancer. Earlier in his career, he worked as the Head of Contract Research for reMYND, a biotech company focused on the development of small molecule therapeutics for the treatment of Alzheimer’s, Parkinson’s and Diabetes. He also worked as an investment analyst at M Ventures, Merck KGaA’s corporate venture capital arm. He holds an MSc in molecular biology and business economics from Leiden University and Delft University of Technology in the Netherlands.

Samantha Macro

VP Head of Finance

Samantha Macro
VP Head of Finance
Samantha is VP, Head of Finance at Mestag Therapeutics. Qualifying as a Chartered Accountant at PwC she spent time in their Cambridge and Brisbane offices. Samantha spent the last 15 years within Life Sciences, initially at Cambridge Antibody Technology - later acquired by AstraZeneca included the integration with MedImmune, where she was part of the leadership teams of three Innovative Medicines Units; Respiratory, Inflammation and Autoimmune; Cardiovascular and Molecular Diseases; and Neuroscience. Samantha then Johnson Matthey Pharma division to support the evolution and strategy of the ex-US region. Prior to joining Mestag, Samantha was the Global Head of Finance for Horizon Discovery Group, supporting the strategic and M&A initiatives while preparing the finance function for a NASDAQ listing, resulting in PerkinElmer acquiring the Group at the end of 2020. Samantha has an MBA and PhD from Loughborough University Business School, latter within the department of International Business and Strategy.

Yuchen Bai

VP Head of Data Science

Yuchen Bai
VP Head of Data Science
Yuchen is a leader in computational biology, with more than 20 years of experience in the pharmaceutical industry (Pfizer, GSK, Janssen and Autolus). He has been working in multiple therapeutic areas such as oncology, immunology and neuroscience across the entire drug development pipeline. The therapeutic modalities that Yuchen has been working on include small molecules, antibodies and cell therapies. Yuchen has extensive experience in next-generation sequencing, multi-omics data analyses, and translational medicine. Recently he has adopted the single-cell omics approach in order to take a deep dive into disease biology and treatment. Yuchen holds a Ph.D. in Molecular Biology from Rutgers University, a Medical Degree from Tianjin Medical University, a MS in Computer Science from Villanova University, and a BS in Biology from Tsinghua University.

Claire Walshe

Program Lead

Claire Walshe
Program Lead
Claire Walshe is Program Lead at Mestag Therapeutics. Claire has over 14 years experience in roles of increasing responsibility across a series of biotechs including Arana Therapeutics (now part of Cephalon inc.), Molecular Vision and most recently Topivert Pharma where she was Head of Biology and Opthalmology Program Lead. Joining Topivert at inception, she was responsible for implementing and executing the biology strategies supporting discovery and translational activities and leading the preclinical development of the ophthalmology program through IND filing and early phase clinical trials. She has a PhD in Cancer Immunology and Immunotherapy from the University of Southampton.

Bojana Popovic

Head of Antibody Discovery

Bojana Popovic
Head of Antibody Discovery
Bojana Popovic started her industry career at Cambridge Antibody Technology (subsequently MedImmune/AstraZeneca) where she worked for more than 12 years in Antibody Discovery and Protein Engineering. Bojana joined the organisation as a computational structural biologist where she was responsible for establishing the company's structural biology capability to support rational drug design of biologics. She led a scientific team to develop and implement novel computational biology technologies and enhance existing platforms to expand the pipeline of antibodies and antibody-based drugs. Bojana drove the integration of the role of protein structure/dynamics and established techniques such as molecular dynamics, free energy perturbation and machine learning into early drug design & discovery. She led a number of early drug discovery projects across various therapy areas with responsibilities for matrix and direct line management. She is excited by research at the interface between technology and biology, is able to define important therapeutic problems and drive innovation to solve them. She is an author of more than 25 publications and thought leader in the rational design of biologics, has been an invited speaker in many prominent conferences and led pre-competitive collaborations across industry. She has a PhD from the University of Cambridge and an undergraduate degree from the University of Edinburgh.

Jane Whitrow

Business Operations Advisor

Jane Whitrow
Business Operations Advisor
Jane Whitrow FCA is the Business Operations Advisor at Mestag Therapeutics. Jane has a degree and PhD in Plant Genetics. She completed one three-year post-doctoral research contract in the same field before joining KPMG to train as a Chartered Accountant. Jane spent five years with KPMG working with a range of clients, primarily in the hi-tech and owner managed business space. In 1997 she was approached to join the biotech venture capitalist Merlin Ventures (latterly Merlin BioSciences) as Financial Controller with a wide-reaching role across both the corporate group and the investment portfolio. She was promoted to Board as Finance Director in 2001. Jane decided to leave Merlin and go freelance in 2003. In the period 2003 to 2020 Jane worked for a number of high tech/start up companies including IXICO, Gyroscope Therapeutics and Freeline Therapeutics providing support in fundraising, forecasting, financial reporting, investor relations, HR, IT, legal, facilities and Company Secretarial.

Sav Bassi

HR Consultant

Sav Bassi
HR Consultant
Sav has been working in HR and Talent Acquisition for the past 20 years. After spending 15 years in the IT industry, Sav has spent the last 5 years working in some of the most innovative companies in biotech, transforming their HR and talent practices. In 2015, he joined Illumina as part of their global HR leadership team helping them through a period of rapid growth. After leaving Illumina in 2019, Sav has been working as a consultant working for biotech start-ups providing HR & Talent Acquisition support. Sav received his MSc in Economics from University of London and completed his executive leadership programs from Yale School of Management in 2018.

Grace Emms

Executive Administrator/ Office Manager

Grace Emms
Executive Administrator/ Office Manager
Grace joined Mestag as their Executive Assistant and Office Manager in November 2020, focusing on supporting Susan Hill and her Leadership Team as well as setting up the office facility. Grace has worked in Business and Executive Support roles for the past 4 years, starting off at a Telecommunications Company. Before joining Mestag, Grace worked for Freeline Therapeutics as their Office Manager and Business Support for the Clinical and Medical Teams. Prior to this Grace was a Personal Assistant at AstraZeneca in the Data Science and Artificial Intelligence Team.

Davide Vito

Data Architect

Davide Vito
Data Architect
Davide is responsible for the development and implementation of Mestag's cloud compute and storage architecture for state-of-the-art data analytics. At Capco Digital he covered data science, software development and cloud computing as part of their graduate training scheme.  He contributed to real world projects as a cloud and data science consultant for global clients. Previously, Davide studied biotechnology and completed his Marie-Curie PhD in antibody production applying transcriptomics and in-silico prediction models in collaboration with academic and industrial partners around the world. These include UCB Pharma where he worked on the integration and analysis of -omics datasets to improve yield of difficult to express biotherapeutics.

Laura Eghobamien

Lead Assay Development Scientist

Laura Eghobamien
Lead Assay Development Scientist
Laura is part of the Antibody Discovery group at Mestag. Her primary role is to develop the functional biological assays that will be used to support antibody discovery projects as well as to help establish and support the laboratory facilities. Laura has spent over 18 years in the biotechnology industry; 4 years at Crescendo Biologics and 14 years at AZ/Medimmune (previously Cambridge Antibody Technology). At Crescendo Biologics she was involved in developing high throughput screening assays to characterise immune checkpoint proteins in support of the development of novel cancer therapeutics. In addition, she served as assay lead in the company’s collaboration with Takeda Pharmaceuticals. At AZ/Medimmune she worked in the Core Biology and Respiratory Inflammation groups developing cell-based assays for inflammatory and respiratory disease indications including rheumatoid arthritis and asthma. She has extensive experience in profiling therapeutic antibody-based drugs from drug discovery through to clinical candidate nomination. Laura holds an MSc in Applied Immunology.

Cameron Field

Discovery Scientist

Cameron Field
Discovery Scientist
Cameron Field is a Discovery Scientist at Mestag Therapeutics, leading the Novel Target Discovery effort. With deep expertise in basic biomedical research encompassing cell biology, immuno-oncology, autoimmunity and immunometabolism, Cameron has a desire to translate basic research into therapeutic opportunities. Previously, Cameron was a Scientist at Quell Therapeutics and a Scientific Consultant for Avalia Immunotherapies, leading mechanism of action studies and the establishment of R&D pipelines respectively. Before moving to London, Cameron spent over 3 years working with Dr Erika Pearce at the Max Planck Institute of Immunobiology and Epigenetics. Cameron has a PhD from the Malaghan Institute of Medical Research and a BSc (Hons 1st Class) from the University of Otago.

Vicki Wright

Project Manager

Vicki Wright
Project Manager
Vicki Wright is a Project Manager at Mestag Therapeutics with 10 years’ experience in Oncology Drug Discovery. Vicki started her industry career as a biologist working at AstraZeneca, before moving into biotech at Redx Pharma. Joining Redx whilst it was a start-up, she successfully led a team of biologists in the development of a small molecule inhibitor for the treatment of B-cell malignancies, which Eli Lilly is now progressing in the clinic. Most recently, whilst working on the development of bispecific antibodies at F-star Therapeutics, Vicki became increasingly interested in the co-ordination of all aspects of the drug discovery process, leading to her move into Project Management. As a Project Manager, Vicki combines expertise in the acceleration of antibody projects with a passion for collaborative working. She has a PhD in Biomedical Science from the University of Sheffield.

Joe Casson

Display Technology Scientist

Joe Casson
Display Technology Scientist
Joe Casson is a Display Technology Scientist in the Antibody Discovery team at Mestag Therapeutics. Joe has extensive experience in molecular biology and protein engineering, with a particular interest in new technologies and their therapeutic applications. He began working in antibody discovery at MedImmune before undertaking a PhD and post-doctoral research on the control of protein translation, localisation, and quality control at the University of Manchester. Prior to joining Mestag, Joe worked on developing the Affimer technology as an alternative to antibody-based therapeutics at Avacta Life Sciences.

Tahira Anwar

Laboratory Manager

Tahira Anwar
Laboratory Manager
Tahira obtained a Master of Science in Biological Science from Sapienza University of Rome in Italy. During her Master thesis project, Tahira studied the relation between hypoxia and autophagy in tumor cells. She then moved to Finland and joined the University of Helsinki to pursue a PhD in Biochemistry where she studied the role of Beclin 1 protein in autophagy. Tahira has extensive experience in cell culturing, western blotting, confocal and electron microscopy, and image analysis. During her PhD she gained extensive experience in laboratory management, playing a fundamental role in the smooth running of her supervisor’s laboratory in Helsinki.

Suhaib Mohammed

Lead Data Scientist

Suhaib Mohammed
Lead Data Scientist
Suhaib Mohammed is Lead Data Scientist at Mestag Therapeutics. He previously worked at EMBL-EBI as a Senior Bioinformatician where he was overseeing the development and managing of data analytics production pipelines for next-generation sequencing-based transcriptomics data. Overall, his professional experience in computational biology spans over 14 years in developing systems biology models and analysing multi-omics data. Before EBI, Suhaib worked at the University of Glasgow closely with GSK pharmaceuticals on a research collaboration to identify potential gene signatures in chronic kidney disease. Previously, he worked in the biopharmaceutical industry, Cellworks Group Inc as Biomodelling Scientist developing in-silico predictive models for therapeutic intervention of type 2 diabetes. Suhaib holds a PhD from the University of Exeter and MRes from the University of Leeds in Bioinformatics & Computational Biology.

Jennifer Galbraith

Research Scientist

Jennifer Galbraith
Research Scientist
Jennifer is a Research Scientist at Mestag where she supports the execution of the biology strategy for early drug discovery programs to underpin the mechanism of action of lead candidates. Prior to joining Mestag, Jennifer started her career in industry at Horizon Discovery where she worked in their R&D and Functional Genomic Screening teams. She was responsible for multidisciplinary research projects and target validation as well as running genome wide pooled CRISPR screening projects for clients in the bio-science industry. During her time at university she completed a placement year in the CRUK Manchester Institute Pre-clinical labs, where she investigated two circulating tumour cell derived explant models of small cell lung cancer. She has a degree in Biochemistry from the University of Bath.

Anamarija Jurisic

Target Discovery Scientist

Anamarija Jurisic
Target Discovery Scientist
Anamarija Jurisic is a Target Discovery Scientist at Mestag Therapeutics. As part of the Target Discovery Team, Anamarija is responsible for the development of complex cellular assays to identify and validate novel drug targets. Bringing strong expertise in molecular and cell biology, immune-oncology and protein homeostasis, Anamarija has a particular interest in creating disease-relevant cellular models as innovative tools in preclinical drug development. Previously, Anamarija was at Almac Discovery, first as an industrial postdoc, and later as a Senior Scientist, leading target validation and mechanism of action studies of a small molecule inhibitor targeting deubiquitinating enzyme USP7. Anamarija has a PhD in Oncology from Paris-Sud University and undergraduate degrees from the University of Zagreb.

Anita McGonagle

Executive Assistant / Finance Assistant

Anita McGonagle
Executive Assistant / Finance Assistant
Anita joined Mestag as an Executive and Finance Assistant in May 2021. Anita has worked in Executive, Finance and Business Support roles in a variety of private healthcare settings and biotech companies in a career spanning over 10 years. Before joining Mestag, Anita worked for Cellinta as the Executive Assistant supporting the CEO and her Leadership Team and prior to this for Freeline Therapeutics as their Office Manager and Business Support for the Operations, Regulatory and Intellectual Property Teams.